PTEN Binding Peptides for Cancer Therapy
Solution Overview
Problem
Current therapies for cancers driven by hyperactive PI3K/AKT/S6K pathway lack effective molecules to directly activate PTEN function, leading to off-target effects and drug resistance due to alternative signaling feedback loops.
Innovation Solution
Development of γ-AAPeptides that bind to PTEN, increasing its lipid phosphatase activity and inhibiting the PI3K/AKT/S6K pathway by enhancing PTEN's ability to reduce PIP3 levels, thereby antagonizing oncogenic signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies target the PI3K/AKT/S6K pathway indirectly, then cancer cell growth can be inhibited, but off-target effects and drug resistance occur due to alternative signaling feedback loops
Solution Approach 1:
The patent uses PTEN as an intermediary molecule to indirectly inhibit the PI3K/AKT/S6K pathway. Instead of directly targeting the pathway components (which causes off-target effects), the compounds activate PTEN, which then naturally regulates the pathway through its lipid phosphatase activity, converting PIP3 to PIP2 and reducing AKT activation. This intermediary approach achieves therapeutic efficacy while avoiding direct interference with the pathway and its feedback loops.
Solution Approach 2:
The invention enables the cell's own PTEN protein to perform its tumor-suppressive function by providing small molecules that restore or enhance its activity. Rather than introducing external agents that directly inhibit the pathway, the compounds allow PTEN to self-regulate the PI3K/AKT/S6K pathway through its endogenous mechanism, thereby avoiding drug resistance associated with external pathway inhibitors.
2Reliability
If PTEN activity is enhanced to inhibit oncogenic signaling, then cancer cell proliferation and migration are reduced, but the complexity of delivering effective PTEN-activating compounds increases
Solution Approach 1:
The patent employs small molecules that undergo specific parameter changes upon entering the cell (e.g., pH-dependent release, conformational changes) to activate PTEN. These parameter changes allow the compounds to transition from stable delivery forms to active PTEN-modulating agents, effectively reducing the complexity of delivery while maintaining therapeutic efficacy. The compounds are designed to change their state or properties in response to cellular conditions, enabling controlled activation of PTEN.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The γ-AAPeptides effectively reduce cancer cell proliferation and migration, induce cell cycle arrest, and inhibit the PI3K/AKT/S6K pathway, offering a potential therapeutic option for cancers with compromised PTEN activity or function.
Implementation Method 1
increasing its lipid phosphatase activity and inhibiting the PI3K/AKT/S6K pathway by enhancing PTEN's ability to reduce PIP3 levels
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
Described herein are compounds and formulations thereof that can bind PTEN. Also described herein are methods of using the compounds and formulations thereof that can bind PTEN. In some embodiments, the method can include administering an amount of a compound or formulation described herein to a subject in need thereof.